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Abstract 
5-Fluorouracil (5-FU) is used widely as an anticancer drug to treat solid cancers, such as colon, breast, rectal, and 
pancreatic cancers; although it’s clinical application is greatly limited by its short plasma half-life, poor tumor affinity, 
myelosuppression, and gastrointestinal toxicity. To tackle these problems, numerous modifications of the 5- Fu structure 
have been performed.Thus, 5-Fu as possible colon specific prodrugs were synthesized in which 5-Fu is attached to amino 
acids (alanine & phenylalanine) using succinate group as a spacer via amide or ester bond. An approach to improve the 
properties of 5-fluorouracil is the chemical transformation into bioreversible derivatives (prodrugs) which are converted to 
the parent drug by enzymatic and / or chemical hydrolysis. The synthesis of the target compounds were accomplished 
following multistep reaction procedures, the chemical reaction followed up and the purity of the products were checked by 
TLC. 
   The structures of the final compounds were confirmed by their melting points, infrared spectroscopy and 
1
H-NMR 
spectra. The hydrolysis of compounds III, IV, V, and VI in aqueous buffer solutions of pH 1.2 and pH 7.4 were studied. 
   Compounds III, IV, V and VI had enough stability at pH 1.2 (t = 429.874min, t =429.874min, t=334.336min and t 
=376.139min respectively) and at pH 7.4 (t=601.823min, t=601.823min, t=429.874min and t=501.519min respectively); 
expecting that hydrolysis of these compounds by microbial enzymes in the colon will deliver 5-fluorouracil spontaneously. 
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Introduction 
Colon cancer is the second cause of cancer related deaths in the world. Although improvements have been made in 
surgical techniques and in chemotherapies, the survival rate is still low [1]. 5-fluorouracil is an antimetabolite of the 
pyrimidine analogue type, which is frequently used for treating solid tumors, such as colorectal, gastric tract, and liver 
carcinomas [2, 3]. 
However, the clinical applications of 5-FU are greatly limited by its short plasma half-life, poor tumor affinity, 
myelosuppression, and strong intestinal toxicity. To tackle these problems, numerous modifications of the 5- Fu structure 
have been performed, thus, a series of 5-Fu prodrugs in which 5-Fu is attached to amino acids, peptides, phospholipids, 
and polymers have been reported [4-7]. 
          The term “prodrug”, first introduced by Albert, refers to a chemically modified form of a drug [8] that is devoid of 
pharmacological activity, but that can be converted to the active form of the drug in a biological system, where it exerts the 
desired action. This strategy can improve the limitations associated with the effective transport into tumor cells, catabolic 
inactivation before the cytotoxic entity can reach the tumor, and short plasma half-1ife [9, 10].  
As the site of drug absorption, the colon holds several drawbacks, such as small surface area, low fluidity of the lipid 
membrane, existence of tighter junction compared to the small intestine, low motility, and high viscosity of intestinal 
contents. On the other hand, long transit time, low proteolytic activity, and responsiveness to the action of absorption 
enhancers are the positive aspects of the large intestine as the site of drug absorption compared to the small intestine 
[11].  
The objective of the colon-targeted drug delivery is to avoid absorption and degradation of drugs in the upper GI tract 
allowing them act site-specifically in the colon and this achieved by various approaches such as pH dependent utilizing the 
changes in pH along the GI tract [12], coated dosage forms [13], time-controlled release systems [14], pressure-controlled 
colon delivery systems [15], coating drugs with bacterially degradable polymer [16] and prodrug based drug delivery 
system [17]. The colonic drug delivery systems are mainly based on degradation of a prodrug by microorganisms of the 
colon flora [18] and colonic enzymes [19]. 
To design a colon-specific prodrug, a parent drug is usually linked to a nonabsorbable carrier such as a polymeric matrix 
or a hydrophilic small molecule to prevent the absorption of the colon-specific prodrug in the upper intestine
 
[20].  
Ho et al. [21] reported that the liver has the highest dihydrouracil dehydrogenase activity with minimal activity in the colon 
and colon tumor. These studies suggest that bioactivation of 5-FU to 5-fluoro-2
’
-deoxyuridine is most active and 
bioinactivation of 5-FU to dihydro-5-FU is the least active in colon tumor. If 5-FU is delivered specifically to colon, the 
active metabolite of 5-FU should be most available in colon tumor, and the systemic side effects of 5-FU will be minimized 
compared with oral administration.  
Spacer or linkers can be used if the desired prodrug promoiety cannot be attached directly to the parent molecule due to a 
sterical hindrance or functional properties of the parent drug. The spacers increase the distance between the parent 
molecule and the promoiety and are usually cleaved spontaneously after the enzymatic or chemical decomposition of the 
prodrug bond between the promoiety and the spacer [22]. 
EXPERIMENTAL PROCEDURE 
Synthesis of methyl ester hydrochlorides of L-phenylalanine and L-Alanine: 
         A suspension of L-Phenylalanine (9 mmole) dissolved in (15 mL) of absolute methanol, was cooled down to -15 
0
C 
then thionyl chloride was added drop wise (9 mmole), (the temperature should be keep below -10
0
C), the reaction mixture 
was left at 40
0
C for 1hr, then refluxed for 4hr and left at room temperature overnight, , It was titrated with 20 ml portion of 
cold ether at 0 
0
C until the excess of dimethyl sulphate was removed, the excess solvent was evaporated to dryness under 
vacuum, re-crystallize the product from methanol-petroleum ether to get pure L-Phenylalanine methyl ester HCl. The same 
procedure was followed to synthesize L-Alanine methyl ester HCl [23]. 
 (S)-methyl-2-amino-3-phenylpropanoate hydrochloride (A). 
       As White crystal (87%yield); m.p.160 c°. Rfvalue=0.65. IR 3425-2623of (NH3
+
Cl
-
), 1747(C=O) of ester, 1629asym. 
bending of (NH3),  1242 and 1145 (C-O-C) cm
-1 
, 742 and 702 (C-H) out of plane bending vibration of monosubstituted  
benzene. 
 (S)-methyl 2-amino propanoate hydrochloride (B). 
        As White crystal (82%yield); m.p. 120 c°. Rfvalue=0.7. IR 3439-2700 (NH3
+
Cl
-
), 1741 (C=O) of ester, 1618 bending of 
(NH3), 1506 (C=C) aromatic, 1253 and 1199 (C-O-C) cm
-1
. 
Synthesis of Intermediate (I): 
        L-Phenylalanine methyl ester HCl (2mmole) was treated with (2mmole) of succinic anhydride in tetrahydrofuran and 
(2mmole) of triethylamine at room temperature for 10 min. The precipitate was filtered and dried without further purification 
to get Intermediate (IA). The same procedure was followed with L-Alanine methyl ester HCl to synthesize Intermediate (IB) 
[24]. 
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(S)-4-(1-methoxy-1-oxo-3-phenylpropan-2-yl amino)-4-oxobutanoic acid Intermediate (IA) 
As white powder (75%yield); m.p.210-212
O
C decompose.Rfvalue=0.75, IR(KBr cm
-1
) 3440 NH of 2
0
 amide, 2500-3000 OH 
str. vibr., 2976, 2941(C-H) of CH3 and CH2, 1745 broad (C=O)of ester and acid, 1653 (C=O) of  2
0 
amide, 1539 (N-H) 
bending of 2
0
 amide, 1477 (C=C) of  benzene, 1442&1394 (C-H) bend of CH2 & CH3, 1172 (C-O), 1240 asym.(C–O–C), 
750 &702 (C-H) out of plane bending vibration of monosubstituted benzene. 
(S)-4-(1-methoxy-1-oxopropan-2-yl amino)-4-oxobutanoic acid Intermediate (IB) 
As white powder (70%yield); m.p.198-200
O
C decompose.Rfvalue=0.79, IR(KBr cm
-1
) 3381 NH of 2
0
 amide, 2500-3000 OH 
str. vibr. , 2978, 2941 (C-H) of CH3& CH2, 1734 (C=O) stretching vibration of ester and acid, 1622 (C=O) str. of 2
0 
amide, 
1593 (N-H) bending of 2
0
 amide, 1448, 1400&1363 (C-H) bend of CH3 & CH2, 1170(C-O), 1232 asym.(C–O–C). 
Synthesis of Intermediate (II): 
            A suspension of intermediate (IA) (2mmole, 0.56g) dissolved in (10ml) of dry chloroform, was cooled down to -
15
0
C then thionyl chloride (2mmole, 0.15mL) was added slowly to it. The mixture was refluxed for 4hr at 60-70
0
C with 
continuous stirring. Then evaporate the excess solvent by using rotary evaporator. The viscous liquid was slowly added 
drop wise into a beaker contain of  2,4–dinitrophenol(2mmole, 0.368g)  dissolved in (5ml) of dry chloroform and 
triethylamine (2mmole, 0.28ml) for 1hr on an ice bath, then continuous stirring overnight at room temperature. The solid 
that separated out was filtered off and washed with dry chloroform to give Intermediate (IIC). The same procedure was 
followed with Intermediate (IB) to give Intermediate (IID) [25]. 
(S)-2,4-dinitrophenyl4-(1-methoxy-1-oxo-3-phenylpropan-2-yl amino)-4-oxobutanoate. Intermediate (IIC) 
As yellowish powder (62%yield);m.p.77-78
O
C.Rfvalue=0.64, IR(KBr cm
-1
)  3269 (N-H) of 2
0 
amide, 3109 (C-H) of aromatic,  
2978, 2945  (C-H) of CH3&CH2, 1743 & 1710 (C=O) of ester, 1626 (C=O) of 2
o
 amide, 1597(N-H) bending of 2
0
 amide , 
1479 (C=C) of  aromatic, 1537 (NO2)anti symm., 1340 (NO2)symm., 1178 (C-O) , 1255 asym. (C–O–C), 1437&1398 (C-
H) bend of CH3&CH2. 
(S)-2,4-dinitrophenyl4-(1-methoxy-1-oxopropan-2-ylamino)-4-oxobutanoate. Intermediate (IID) 
As brownish powder (65%yield);m.p. 68-70
O
C.Rfvalue=0.57, IR(KBr cm
-1
) 3269 (N-H) of 2
0 
amide, 3107 (C-H) of aromatic, 
2976, 2939  (C-H) of CH3&CH2, 1739 (C=O) stretching vibration of ester, 1626 (C=O) of 2
o
 amide, 1599 (N-H)  bending of 
2
0
 amide, 1477 (C=C) of aromatic, 1537 (NO2)   anti symm. , 1340 (NO2) symm., 1180 (C-O), 1257 asymm. (C–O–C), 
1435&1394 (C-H) bend of CH3&CH2. 
Synthesis of compound (III) & (IV): 
             A suspension of intermediate (IA) (2mmole, 0.56g) dissolved in (10ml) of dry chloroform, and was cooled down to 
-15
0
C then thionyl chloride (2mmole, 0.15mL) was added slowly to it. The mixture was refluxed for 4hr at 60-70
0
C with 
continuous stirring. Then evaporate the excess solvent by using rotary evaporator. The viscous liquid was slowly added 
drop wise into a beaker contain  5-fluorouracil (2mmole, 0.26g)  dissolved in a dry 1,4 dioxane (5mL) and triethylamine 
(2mmole, 0.28ml) for 1hr on an ice bath, then stirring overnight at room temperature. The obtained suspension was filtered 
and the filtrate was washed with distilled water (20ml), dried with anhydrous magnesium sulfate and the solvent was 
evaporated by vacuum. The obtained compound was crystallized from diethyl ether-petroleum ether to give compound 
(III). The same procedure was followed with Intermediate (IB) to give compound (IV) [26]. 
Methyl2-(4-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-oxobutanamido)-3-phenylpropanoate. Compound 
(III) 
As white powder (77%yield);m.p. 175-176
O
C.Rfvalue=0.82, IR (KBr cm
-1
)  3263 (N-H) of 2
0
amide, 3142 (N-H) of 
pyrimidine, 3059 (C-H) of aromatic , 2987 & 2827 (C-H)of CH3&CH2, 1718, 1479 & 1394 NH(C=O)-C=C-amide I, II and III 
(str. vibr.) of uracil and C=C of benzene ring,1668 (C=O) of 2
0
 amide,1247 (C-F)1213 asym.(C–O–C), 1440 (C-H) bend of 
CH3 & CH2, 1170 (C-O), 750 and 715 (C-H) out of plane bending vibration of monosubstituted benzene. 
1
H-NMR (300MZ, 
DMSO-d6):11.8 ( 1H, NH
*
 of 5-FU), 10.3 ( 1H, NH
*
  of  CONH ), 8.413 (1H,  CH
*
 of FC=CH), 7.587 - 6.135 (5H, Ar-H
*
), 
4.558 (1H, CH
*
 of  CHNHCO), 3.165 ( 3H, OCH
*
3), 2.888-2.867  (2H, CH
*
2-Ar), 1.009-0.987 (4H, CH
*
2CH
*
2). 
Methyl2-(4-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-oxobutanamido)-3-propanoate. Compound (IV) 
As white powder (80%yield);m.p. 164-166
O
C.Rfvalue=0.8, IR (KBr cm
-1
)  3136 (N-H) of 2
0
 amide,3064(N-H)of pyrimidine, 
2978, 2937 (C-H) of CH3&CH2, 1718, 1479 & 1394 NH(C=O)-C=C-amide I, II, and III (str.vib.) of uracil, 1668 (C=O of 2
0
 
amide,1249 (C-F),1213 asym.(C–O–C), 1437 (C-H) bend of CH3 & CH2,1172 (C-O). . 
1
H-NMR (300MZ, DMSO-d6): 11.5 
(1H, NH
*
 of 5-FU), 10.6 (1H, NH
* 
of CONH), 7.75 (1H, CH
* 
of FC=CH), 3.68 (1H, CH
* 
of CHNHCO), 3.17 (3H, OCH3
*
), 
1.37-1.18 (7H, CH2
*
 CH2
*
, CCH3
*
). 
Synthesis of Compound (V) & (VI): 
          The reaction of Intermediate (IIC) (1 mmole, 0.446g) and 5-fluorouracil as sodium salt (2mmole, 0.306g) in absolute 
ethanol (10ml) was refluxed for three hours at 65
0
C. The formed precipitate was filtered, washed with cold ethanol and re-
crystallized from ethanol as a pale yellow crystal of compound (V). The same procedure was followed with Intermediate 
(IID) to give pale brown crystals of compound (VI) [27]. 
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5-fluoro-6-oxo-1,6-dihydropyrimidine-2-yl4(1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-4-oxobutanoate. 
Compound (V) 
As pale yellow powder (60%yield);m.p.129-130
O
C.Rfvalue=0.7, IR (KBr cm
-1
)  3128 (N-H) of 2
0
 amide,3068(N-H) of 
pyrimidine, 2982, 2937& 2825 (C-H) of CH3&CH2, 1724, 1483 & 1396 NH(C=O)-C=C-amide I, II, and III (str.vib.) of uracil 
and C=C of benzene ring, 1664 (C=O) of 2
0
 amide,  1247 (C-F), 1176 asymm. (C–O–C), 1435 & 1336(C-H) bend of CH3 
& CH2, 1128(C-O), 752 and 719 (C-H) out of plane bending vibration of monosubstituted benzene.
 1
H-NMR (300MZ, 
DMSO-d6): 11.30 ( 1H, NH
*
 of 5-FU), 10.4 ( 1H, NH
*
  of  CONH ), 8.416 (1H,  CH
*
 of FC=CH), 7.584 - 6.118 (5H, Ar-H
*
), 
4.286 (1H,  CH
*
 of  CHNHCO), 3.162  ( 3H, OCH
*
3),  2.851-2.827 ( 2H, CH
*
2-A r), 1.018-0.972  (4H, CH
*
2CH
*
2). 
5-fluoro-6-oxo-1,6-dihydropyrimidine-2-yl4(1-methoxy-1-oxopropan-2-ylamino)-4-oxobutanoate. Compound (VI) 
As pale brown powder (55%yield); m.p.140-142
O
C.Rfvalue=0.77, IR (KBr cm
-1
) 3132 (N-H) of 2
0
 amide,3066(N-H) of 
pyrimidine, 2980,2937(C-H) of CH3&CH2, 1724, 1483& 1396 NH(C=O)-C=C-amide I, II, and III (str.vib.) of uracil,1662 
(C=O) of 2
0
 amide,1247 (C-F),1176 asymm. (C–O–C), 1435 & 1325(C-H) bend of CH3 & CH2, 1078(C-O). 
1
H-NMR 
(300MZ, DMSO-d6): 11.50 (1H, NH
*
 of 5-FU), 10.6 (1H, NH
* 
of CONH), 7.75 (1H, CH
* 
of FC=CH), 3.32 (1H, CH
* 
of 
CHNHCO), 3.08 (3H, OCH
*
3), 1.22-0.99 (7H, CH
*
2CH
*
2, CCH
*
3). 
Preliminary kinetic study of 5-fluorouracil derivatives at pH 1.2, pH 7.4: 
       The stability of 5-fluorouracil derivatives was studied in (0.2M) HCl solution (pH 1.2) [85ml (0.2M) HCl + 50ml (0.2 M) 
KCl, Distilled water, ad. to 200ml] and in (0.1M) phosphate buffer solution (pH 7.4) [100ml (0.1 M) KH2PO4 + 78.2ml (0.1 
M) NaOH, Distilled water, ad. to 200ml] incubated at 37C. The total buffer concentration was 0.1 M and the ionic strength 
(μ) 1.0 was maintained for each buffer by addition of calculated amount of NaCl. The rate of hydrolysis was followed 
spectrophotometrically (UV method) by recording the decreases in the absorbance of   5-fluorouracil derivatives 
accompanying the hydrolysis. The reactions were initiated by adding 1 ml of stock solutions (1mg ml) of the derivatives in 
methanol to preheated buffer solution at 37C to give final concentration of derivatives (0.02mg ml).  The solutions were 
kept in a water bath at 37C and samples (3ml) were withdrawn at appropriate time interval (15, 30, 60,120 and 240 min.) 
and the absorbances were recorded.  The observed first rate constants were determined from the slopes of the linear plots 
of log. concentration remaining versus time [28]. 
Results and Discussion 
The synthetic pathways for the designed target compounds (III- VI) are illustrated in (scheme 1) 
Scheme1. Synthesis of target compounds (III- VI) & their intermediates. 
Intermediate (IA, IIC)     (If      R=  Phenylalanine) 
Compound (III, V) 
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Intermediate (IB, IID)     (if     R=CH3                          Alanine) 
Compound (IV, VI) 
 
Kinetic study: 
      The max of fluorouracil 265 nm was the same max of compounds III, IV, V and VI, but they differ in molar 
absorpitivity (E) according to the Beer-Lambert equation [29]: 
A=E c b -------- equation (1) 
    Thus making UV method relevant for studying the hydrolysis of these analogues, so the amount of fluorouracil alone 
was calculated from the following equation [29]: 
AT = ER [R]-ER [P] + EP [P] -------- equation (2) 
Where: 
AT= absorption at any time 
ER= the molar absorpitivity of compound III, IV, V and VI at pH 1.2 & 7.4 
[R]= the initial concentration of each compound III, IV, V and VI 
EP= the molar absorpitivity of 5-FU at pH 1.2 & 7.4 
[P]= the concentration of 5-FU 
      Under experimental conditions used the hydrolysis of the 5-fluorouracil derivatives followed pseudo first order kinetics, 
since plots of log concentration of 5-fluorouracil alone vs. time resulted in straight lines, from their slopes; the observed 
rate constants of hydrolysis were calculated. Figures (1), (2) ,(3) and (4) are represented graphs for pH stability profile of 
the compounds III, IV, V and VI  respectively; while table (1) shows the pH values, the corresponding Kobs and half-life of 
the hydrolysis of 5-fluorouracil analogues. The half-life was calculated using equation (4), which derives from the first order 
kinetic law [equation (3)].   
log. C = log. Co – k t / 2.303 -------- equation (3) 
t 1/2 = 0.693 / Kobs    -------- equation (4) 
Table (1) the rate constant of hydrolysis of compounds III, IV, V and VI at pH 1.2 and pH 7.4 at 37C. 
compound pH Kobs(min
-1
) t½(min) 
III   
1.2 
7.4 
  1.612110
-3
 
  1.151510
-3
 
     429.874 
     601.823 
 
IV 
1.2 
7.4 
  1.612110
-3
 
  1.151510
-3
 
      429.874 
     601.823 
 
V 
1.2 
7.4 
  2.072710
-3
 
  1.612110
-3
 
      334.346 
     429.874 
 
VI 
1.2 
7.4 
1.842410
-3
 
1.381810
-3
 
    376.139 
    501.519 
 
 
One of the crucial requirements for a prodrug is that used, it should show a good stability in aqueous solutions and in 
gastrointestinal fluid, and it should be readily hydrolyzed following gastrointestinal absorption to release the parent drug 
[30]. 
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Figure (1) the hydrolysis of compound III in 0.1M HCl solution (pH 1.2) and phosphate buffer (pH 7.4) at 37°C  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (2) the hydrolysis of compound IV in 0.1M HCl solution (pH 1.2) and phosphate buffer (pH 7.4) at 37°C 
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Figure (3) the hydrolysis of compound V in 0.1M HCl solution (pH 1.2) and phosphate buffer (pH 7.4) at 37°C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4) the hydrolysis of compound VI in 0.1M HCl solution (pH 1.2) and phosphate buffer (pH 7.4) at 37°C 
 
Conclusion: 
The synthetic procedure for the designed target compound was successfully achieved and the structural formula for 
the synthetic compound was characterized using IR spectroscopy, 
1
H-NMR, melting points and Rf values. Preliminary 
kinetic study for compounds III, IV, V and VI revealed that these compounds were stable at pH 1.2 and pH 7.4. 
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